Advertisement
Organisation › Details
Vaximm GmbH
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM also has a neoantigen program (VXM NEO) currently in preclinical development; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches. VAXIMM has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM’s investors include: BB Biotech Ventures, BioMed Partners, CMS, M Ventures and Sunstone Capital. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. *
Start | 2011-01-15 existent | |
Group | Vaximm (Group) | |
Predecessor | Merck KGaA | |
Industry | therapeutic vaccine | |
Industry 2 | VXM01 cancer vaccince | |
Person | Lubenau, Heinz (Vaximm 201101 Managing Director Vaximm GmbH before BioGeneriX before Servier) | |
Region | Mannheim | |
Country | Germany | |
Street | 1 Julius-Hatry-Str. | |
City | 68163 Mannheim | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Vaximm AG. (11/12/19). "Press Release: NEC and Vaximm Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines". Tokyo, Basel & Mannheim. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Vaximm (Group)
- [1] Vaximm AG. (3/8/22). "Press Release: NEC OncoImmunity Acquires Vaximm’s Neoantigen Vaccine Development Assets". Oslo, Tokyo, Basel & Mannheim....
- [2] Vaximm AG. (11/12/19). "Press Release: NEC and Vaximm Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines". Tokyo, Basel & Mannheim....
- [3] Vaximm AG. (5/18/17). "Press Release: VAXIMM Announces Data from Phase I Trial in Glioblastoma with Oral T-cell Immunotherapy VXM01 to be Presented at ASCO 2017 Annual Meeting". Basel & Mannheim....
- [4] Vaximm AG. (5/9/17). "Press Release: Vaximm Announces Collaboration with Merck KGaA, Darmstadt, and Pfizer to Evaluate Combination of VXM01 with Avelumab in Glioblastoma and Colorectal Cancer in Phase I/II Clinical Studies". Basel & Mannheim....
- [5] Noxxon Pharma N.V.. (2/10/17). "Press Release: Noxxon Pharma Announces Experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to Serve as Noxxon CMO". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top